Guselkumab in moderately to severely active ulcerative colitis: Another interleukin-23p19 subunit inhibitor or more?

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-03-14 DOI:10.1016/j.medj.2025.100605

Ambrogio Orlando, Fabio Salvatore Macaluso

引用次数: 0

Abstract

The QUASAR clinical development program evaluated the efficacy of guselkumab-an IL-23p19 subunit inhibitor-for the treatment of moderate-to-severe ulcerative colitis.¹ Guselkumab demonstrated rapid control of symptoms, as well as significant rates of objective disease remission. However, real-world evidence will be crucial to confirm these findings in patient subgroups that were not included in the QUASAR program.

查看原文本刊更多论文

Guselkumab治疗中度至重度活动性溃疡性结肠炎：另一种白细胞介素-23p19亚基抑制剂或更多？

QUASAR临床开发项目评估了guselkumab（一种IL-23p19亚基抑制剂）治疗中重度溃疡性结肠炎的疗效Guselkumab表现出症状的快速控制，以及显著的客观疾病缓解率。然而，真实世界的证据将是至关重要的，以证实这些发现在病人亚组，不包括在类星体计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.